Emergent Biosolutions Inc (EBS) Expected to Post Earnings of $0.59 Per Share

Wall Street brokerages expect Emergent Biosolutions Inc (NYSE:EBS) to report earnings of $0.59 per share for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Emergent Biosolutions’ earnings, with the lowest EPS estimate coming in at $0.46 and the highest estimate coming in at $0.71. Emergent Biosolutions posted earnings of $0.74 per share in the same quarter last year, which indicates a negative year over year growth rate of 20.3%. The company is scheduled to announce its next quarterly earnings report on Thursday, February 22nd.

According to Zacks, analysts expect that Emergent Biosolutions will report full year earnings of $1.58 per share for the current financial year, with EPS estimates ranging from $1.49 to $1.72. For the next financial year, analysts forecast that the firm will report earnings of $2.36 per share, with EPS estimates ranging from $1.84 to $2.70. Zacks Investment Research’s EPS calculations are an average based on a survey of research firms that that provide coverage for Emergent Biosolutions.

Emergent Biosolutions (NYSE:EBS) last released its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported $0.73 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.41 by $0.32. Emergent Biosolutions had a return on equity of 15.20% and a net margin of 15.60%. The business had revenue of $149.43 million for the quarter, compared to analysts’ expectations of $124.55 million. During the same quarter in the previous year, the firm posted $0.56 earnings per share. The company’s revenue was up 4.6% compared to the same quarter last year.

EBS has been the topic of several research reports. Zacks Investment Research cut Emergent Biosolutions from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, December 19th. Wells Fargo & Co restated an “outperform” rating and set a $43.00 price objective (up previously from $41.00) on shares of Emergent Biosolutions in a research note on Saturday, September 30th. One research analyst has rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company. Emergent Biosolutions currently has an average rating of “Buy” and an average target price of $47.67.

Emergent Biosolutions (EBS) traded down $0.04 during trading hours on Monday, hitting $47.78. The company had a trading volume of 206,553 shares, compared to its average volume of 289,767. Emergent Biosolutions has a fifty-two week low of $27.94 and a fifty-two week high of $48.47. The firm has a market capitalization of $1,970.00, a PE ratio of 29.86, a price-to-earnings-growth ratio of 0.92 and a beta of 1.29. The company has a debt-to-equity ratio of 0.38, a quick ratio of 6.46 and a current ratio of 7.37.

In other news, Director Zsolt Harsanyi sold 7,000 shares of the company’s stock in a transaction that occurred on Thursday, December 7th. The stock was sold at an average price of $42.47, for a total transaction of $297,290.00. Following the completion of the transaction, the director now directly owns 37,077 shares of the company’s stock, valued at $1,574,660.19. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Daniel Abdun-Nabi sold 31,508 shares of the company’s stock in a transaction that occurred on Friday, November 3rd. The shares were sold at an average price of $42.77, for a total value of $1,347,597.16. Following the transaction, the chief executive officer now directly owns 215,642 shares of the company’s stock, valued at $9,223,008.34. The disclosure for this sale can be found here. Insiders have sold 206,329 shares of company stock worth $8,892,362 in the last 90 days. 16.50% of the stock is currently owned by insiders.

Large investors have recently bought and sold shares of the company. Riverhead Capital Management LLC grew its holdings in shares of Emergent Biosolutions by 102.8% during the second quarter. Riverhead Capital Management LLC now owns 3,042 shares of the biopharmaceutical company’s stock valued at $103,000 after purchasing an additional 1,542 shares during the last quarter. Ameritas Investment Partners Inc. grew its holdings in shares of Emergent Biosolutions by 23.2% during the second quarter. Ameritas Investment Partners Inc. now owns 3,118 shares of the biopharmaceutical company’s stock valued at $106,000 after purchasing an additional 587 shares during the last quarter. First Quadrant L P CA bought a new position in shares of Emergent Biosolutions during the third quarter valued at approximately $157,000. Victory Capital Management Inc. bought a new position in shares of Emergent Biosolutions during the third quarter valued at approximately $191,000. Finally, Meeder Asset Management Inc. grew its holdings in shares of Emergent Biosolutions by 94.7% during the third quarter. Meeder Asset Management Inc. now owns 4,732 shares of the biopharmaceutical company’s stock valued at $191,000 after purchasing an additional 2,302 shares during the last quarter. 88.44% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “Emergent Biosolutions Inc (EBS) Expected to Post Earnings of $0.59 Per Share” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The legal version of this article can be read at https://www.dispatchtribunal.com/2018/01/11/emergent-biosolutions-inc-ebs-expected-to-post-earnings-of-0-59-per-share.html.

About Emergent Biosolutions

Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).

Get a free copy of the Zacks research report on Emergent Biosolutions (EBS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply